Here's some introductory information regarding the primary source of evidence: the journal Neurology, a publication of The American Academy of Neurology - AAN -- from the U.S. Department of Health and Human Services:
American Academy of Neurology - AAN
Organization URL(s)
memberservices@aan.com
www.aan.com
Other Contact Information
1080 Montreal Avenue
St. Paul, MN 55116
800-879-1960 (Voice - Toll-free)
651-695-2717 (Voice)
651-695-2791 (FAX)
Description
The American Academy of Neurology (AAN) is a professional society composed of neurologists and professionals in related fields who share a common goal of continued growth and development of the neurological sciences.
Online Resources
Find a Neurologist
http://www.aan.com/membersearch/
Print Resources
The Academy publishes several brochures on neurology which are used by members for patient information. The Patient Information Guide for Neurology lists organizations which can supply information and materials on specific diseases. The publication, Neurologist, describes what a neurologist is and does. Serial publications: Neurology (journal), monthly; AANews (newsletter), monthly.
Here is some info from wikipedia on AAN:
The American Academy of Neurology (AAN) is a professional society for neurologists and neuroscientists. As a medical specialty society it was established in 1949 to advance the art and science of neurology, and thereby promote the best possible care for patients with neurological disorders.
Annual Meeting The annual meeting of the AAN is attended by more than 15,000 neurologists and neuroscientists from the US and abroad. The 2007 meeting will be in Boston featuring scientific presentations and educational courses. Plenary presentations on three days will highlight cutting edge clinical, translational and basic research. The annual "Future of Neuroscience" conference is titled "Therapies of Genetic Disorders" and will feature talks on enzyme replacement, gene therapy, siRNA, and stem cells ([1]).
Here is the study abstract:
NEUROLOGY 2007;69:536-545
© 2007 American Academy of Neurology
The neuroprotective effects of caffeine
A prospective population study (the Three City Study)
K. Ritchie, PhD, I. Carrière, PhD, A. de Mendona, MD, PhD, F. Portet, MD, PhD, J. F. Dartigues, MD, PhD, O. Rouaud, MD, P. Barberger-Gateau, MD, PhD and M. L. Ancelin, PhD
From INSERM U888 (K.R., I.C., F.P., A.d.M., M.L.A.), Montpellier; INSERM U593 (J.F.D., P.B.-G.), Bordeaux University 2; INSERM U708 (O.R.), University of Paris, France; and Department of Neurology and Laboratory of Neurosciences (A.d.M.), University of Lisbon, Portugal.
Address correspondence and reprint requests to Dr. Karen Ritchie, INSERM U888 Nervous System Pathologies: Epidemiological and Clinical Research, La Colombière Hospital, 34093 Montpellier Cedex 5, France ritchie@montp.inserm.fr
Objective: To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over.
Methods: Participants were 4,197 women and 2,820 men from a population-based cohort recruited from three French cities. Cognitive performance, clinical diagnosis of dementia, and caffeine consumption were evaluated at baseline and at 2 and 4 year follow-up.
Results: Caffeine consumption is associated with a wide range of sociodemographic, lifestyle, and clinical variables which may also affect cognitive decline. Multivariate mixed models and multivariate adjusted logistic regression indicated that women with high rates of caffeine consumption (over three cups per day) showed less decline in verbal retrieval (OR = 0.67, CI = 0.53, 0.85), and to a lesser extent in visuospatial memory (OR = 0.82, CI = 0.65, 1.03) over 4 years than women consuming one cup or less. The protective effect of caffeine was observed to increase with age (OR = 0.73, CI = 0.53, 1.02 in the age range 65 to 74; OR = 0.3, CI = 0.14, 0.63 in the range 80+). No relation was found between caffeine intake and cognitive decline in men. Caffeine consumption did not reduce dementia risk over 4 years.
Conclusions: The psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia.
--------------------------------------------------------------------------------
*These authors contributed equally to this work.
The 3C Study is conducted under a partnership agreement among INSERM, the Victor Segalen–Bordeaux II University, and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and first phase of the study. The 3C-Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, the Institut de la Longévité, Agence Franaise de Sécurité Sanitaire des Produits de Santé, the regional governments of Aquitaine, Bourgogne, and Languedoc-Roussillon, and the Fondation de France, the Ministry of Research-INSERM Programme "Cohorts and collection of biological material." The Lille Génopôle received an unconditional grant from Eisai.
Disclosure: The authors report no conflicts of interest.
Received November 30, 2006. Accepted in final form March 5, 2007.
Copyright © 2007 by AAN Enterprises, Inc.
For a mainstream medical version of this story, please click here to read: "Caffeine Protects Thinking And Memory In Older Women."
I guess the good old 'caf is better for women than men...I wonder why? Could it be possible due to the smaller sample size of women?
Participants were 4,197 women and 2,820 men
Thoughts or comments?
Take care.